RegenxBio touts positive data for rare disease drug RGX-121
RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.
RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.
What's Your Reaction?
